
Colorectal Cancer
Latest News
Latest Videos

CME Content
More News

Stacey A. Cohen, MD, and Daniel H. Ahn, DO, share their key takeaways on the clinical utility of ctDNA in the treatment of patients with colorectal cancer.

Experts on colorectal cancer brainstorm ways to optimize clinical research on ctDNA and discuss patient perceptions of ctDNA testing.

Medical professionals explore methods for integrating circulating tumor DNA results with radiographic and pathologic findings to optimize patient care.

The panel examines a clinical scenario, detailing their approach to circulating tumor DNA testing, including turnaround times, and providing insights on patient counseling.

Shield, the first FDA-approved blood test for CRC screening, may offer convenient screening access for those who are at average risk for the disease.

Daniel H. Ahn, DO, and Stacey A. Cohen, MD, discuss the COBRA clinical trial, which evaluated rates of ctDNA clearance in patients with colorectal cancer receiving assay-directed therapy.

Stacey A. Cohen, MD, and Daniel H. Ahn, DO, provide comprehensive insights on the DYNAMIC clinical trial, an interventional study of circulating tumor DNA in colorectal cancer.

Panelists analyze observed obstacles to implementing routine circulating tumor DNA testing as a standard of care, while offering strategies to overcome these challenges.

Panelists explore the clinical value of circulating tumor DNA testing at various stages of the colorectal cancer treatment journey, with a focus on optimal testing timelines.

Colorectal cancer specialists review recent updates from BESPOKE-CRC evaluating the utilization of circulating tumor DNA for informing adjuvant therapy in patients with colorectal cancer.

The recommendation was made following mid-stage, end-of-phase 2 data for the botensilimab/balstilimab combination, which yielded lower responses in patients.

Jagoda Misniakiewicz, PharmD, discussed implementing fruquintinib into clinical practice and how it's mechanism of action compares with others in the space.

Experts outline circulating tumor (ct) DNA analysis, detailing the two main techniques and their respective advantages and disadvantages.

The EA2201 trial assessed nivolumab plus ipilimumab and short-course radiation therapy for patients with locally advanced rectal cancer.

HRQOL data from the CheckMate 8HW trial may further support frontline nivolumab/ipilimumab for those with MSI-H or dMMR metastatic colorectal cancer.

Arvind Dasari, MD, MS, outlines the evolution of colorectal cancer screening, addressing historical challenges, and the development of non-invasive screening techniques.

Leading experts offer insights into colorectal cancer, including its prevalence, staging, and the current landscape of treatment options.

Data from FRESCO-2 support the approval of fruquintinib for those with previously treated metastatic colorectal cancer in the European Union.

Data from the colorectal cancer cohort of the KRYSTAL-1 trial support the accelerated approval of adagrasib/cetuximab in KRAS G12C–mutated disease.

Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

Phase 2 data show that vaccination with PolyPEPI1018 may enhance the efficacy of atezolizumab in those with microsatellite stable metastatic CRC.

The addition of liver transplant to chemotherapy in those with colorectal cancer and liver metastases boosted overall survival.

Surgical oncologists from Cleveland Clinic discuss the National Accreditation Program for Rectal Cancer and its aim to improve patient outcomes.

Treatment with complete mesocolic excision appears to reduce the length of hospital stay compared with conventional surgery in right colon cancer.

Investigators may continue to reevaluate the benefits of the AI navigator MyEleanor over time in other patient populations.